Skip to content

Study · Observational study · n = 170 · 2023

3 results

Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty.

Ray LA, Eckert GJ, Eugster EA

Journal of pediatric endocrinology & metabolism : JPEM11 Jan 2023Cited by 4 (Europe PMC)

PMID36625262 (opens in a new tab)DOI10.1515/jpem-2022-0557 (opens in a new tab)PepBankPUB-36625262
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In children with CPP, pubertal development regressed or remained stable in the vast majority during histrelin treatment.

    In plain wordsIn children with CPP, puberty regressed or remained stable in most patients during histrelin treatment.

    Peptide
    Histrelin
    Outcome
    MixedPubertal development
    Study

    n = 170

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · average 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Pubertal development regressed or remained stable in the vast majority of patients and biochemical suppression was maintained.
    1 context sentence
    Summary · context
    We performed a retrospective study of 170 children with central precocious puberty treated with a single histrelin implant for more than 1 year.
  2. 02HumanObservational studyEfficacy outcome

    In children with CPP, histrelin maintained biochemical suppression.

    In plain wordsIn children with CPP, histrelin maintained hormone suppression.

    Peptide
    Histrelin
    Outcome
    Not applicableBiochemical suppression
    Study

    n = 170

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · average 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Pubertal development regressed or remained stable in the vast majority of patients and biochemical suppression was maintained.
    1 context sentence
    Summary · context
    We performed a retrospective study of 170 children with central precocious puberty treated with a single histrelin implant for more than 1 year.
  3. 03HumanObservational studySafety outcome

    In children with CPP, time since histrelin implantation showed no correlation with implant breakage or a second incision.

    In plain wordsIn children with CPP, implant duration showed no link to breakage or a second incision.

    Peptide
    Histrelin
    Outcome
    No significant changeComplications versus implant duration
    Study

    n = 170

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · average 24 monthsAs given in this study (human).

    Source sentences

    Summary
    No correlation between time since an implant was placed and complications such as implant breakage or a second incision was seen.
    1 context sentence
    Summary · context
    We performed a retrospective study of 170 children with central precocious puberty treated with a single histrelin implant for more than 1 year.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.